Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

BARD1 LIFE SCIENCES LIMITED

INVESTOR PRESENTATION - BARD1 LIFE SCIENCES LIMITED

ASX:BD1

BARD1 LIFE SCIENCES LIMITED

Health Care

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Read more

Market Cap

$57.47m

Price at Close

$0.024

4w avg. Volume

2.19m

4w avg. Turnover

$53.53k

Announcements
announcementt+2 movementdate
  • Results of Meeting

    Notice Of Meeting

  • -

    26 Nov 2020

-

26 Nov 2020
  • AGM & CEO Presentations and Chairman's Transcript

    Periodic Reports · Market sensitive

  • -

    26 Nov 2020

-

26 Nov 2020
  • Consolidation/Split - BD1

    Issued Capital

  • +4.35%

    25 Nov 2020

+4.35%

25 Nov 2020
  • Helen Fisher Steps Down from BARD1 Board

    Company Administration

  • +4.35%

    25 Nov 2020

+4.35%

25 Nov 2020
  • BARD1 Gains New High-volume Customer for its hTERT Test

    Progress Report · Market sensitive

  • -8.00%

    22 Nov 2020

-8.00%

22 Nov 2020
  • Appendix 4C and Quarterly Activities Report

    Commitments test entity quarterly reports · Market sensitive

  • -4.00%

    30 Oct 2020

-4.00%

30 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -4.00%

    27 Oct 2020

-4.00%

27 Oct 2020
  • Notice of AGM ASX Listing Rule 3.13.1

    Notice Of Meeting

  • +4.00%

    19 Oct 2020

+4.00%

19 Oct 2020
  • Successful BARD1 Kit Evaluation

    Progress Report · Market sensitive

  • -3.70%

    22 Sep 2020

-3.70%

22 Sep 2020
  • BARD1 Awarded BTB Funding to Develop Breast Cancer Test

    Progress Report · Market sensitive

  • 0.00%

    02 Sep 2020

0.00%

02 Sep 2020
Market Data

Current Price

$0.024

52WK HIGH

$0.04

52WK LOW

$0.019

1YR RETURN

-30.30%

1YR RETURN VS. SECTOR

-42.20%

90 DAY RETURN

-20.69%

ASX RANK

1,065

/2,024

SECTOR RANK

9

/14

SHARES OUTSTANDING

2.39b
ASX:BD1

BARD1 LIFE SCIENCES LIMITED

Health Care

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Read more

Market Cap

$57.47m

Price at Close

$0.024

4w avg. Volume

2.19m

4w avg. Turnover

$53.53k

ASX:BD1 is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.